Kura Oncology (KURA)

$8.35 -0.11 (-1.30%)
Market Cap 736.17M
Revenue (ttm) 53.88M
Net Income (ttm) -173.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -322.90%
Debt to Equity Ratio 0.04
Volume 1,733,600
Avg Vol 1,534,792
Day's Range N/A - N/A
Shares Out 87.02M
Stochastic %K 80%
Beta 0.23
Analysts Strong Sell
Price Target $32.45

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC;...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 500 8800
Address:
4930 Directors Place, Suite 500, San Diego, United States
PennyPoacher
PennyPoacher Feb. 23 at 9:27 PM
$KURA has there been a PR that states when ER is? Or does the company not PR a date/time for that?
1 · Reply
biochirp
biochirp Feb. 23 at 7:23 PM
$KURA cash position almost as high as the market cap, buy a drug launch for free at these prices
0 · Reply
Olena
Olena Feb. 23 at 6:31 PM
$KURA have a feeling it will tank in this er temporarily. Will load …
0 · Reply
maybeme54
maybeme54 Feb. 23 at 4:09 PM
$KURA Forecasted KURA Stock Price (March 2026 - 12 Month Outlook) Average Target: ~$28.00–$32.45 High Estimate: $40.00–$76.00 Low Estimate: $16.00–$20.00
0 · Reply
Olena
Olena Feb. 22 at 8:08 PM
$KURA https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-highlights-recent-accomplishments-preliminary
0 · Reply
Olena
Olena Feb. 21 at 8:00 PM
$KURA will it take another 12 months for it to reach $16-20?
1 · Reply
Zvizdamat
Zvizdamat Feb. 20 at 5:50 PM
$KURA $SNDX you are welcome!
2 · Reply
Oscarca
Oscarca Feb. 20 at 2:31 PM
$KURA
0 · Reply
AdiDasRom
AdiDasRom Feb. 20 at 10:36 AM
$KURA
0 · Reply
quickaspeter
quickaspeter Feb. 19 at 1:27 PM
$KURA - FDA will drop two-study requirement for new drug approvals, aiming to speed access. - Going forward, the FDA’s “default position” will be to require one study for new drugs and other novel health products, FDA Commissioner Dr. Marty Makary and a top deputy, Dr. Vinay Prasad, wrote in a New England Journal of Medicine piece published Wednesday February 18, 2026.
1 · Reply
Latest News on KURA
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 6, 2026, 7:30 AM EST - 17 days ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy

Jan 22, 2026, 7:34 AM EST - 4 weeks ago

Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

Jan 11, 2026, 5:00 PM EST - 6 weeks ago

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript

Dec 8, 2025, 5:17 PM EST - 2 months ago

Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

Dec 8, 2025, 10:30 AM EST - 2 months ago

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

Kura Oncology: A Cautious Buy

Dec 4, 2025, 8:08 AM EST - 2 months ago

Kura Oncology: A Cautious Buy

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

Dec 3, 2025, 8:32 AM EST - 2 months ago

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data

Dec 2, 2025, 6:36 PM EST - 2 months ago

Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

Dec 2, 2025, 8:02 AM EST - 2 months ago

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

Nov 25, 2025, 5:16 PM EST - 3 months ago

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript

Nov 19, 2025, 5:23 PM EST - 3 months ago

Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Nov 13, 2025, 10:51 AM EST - 3 months ago

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

US FDA approves Kura Oncology's blood cancer therapy

Nov 13, 2025, 10:32 AM EST - 3 months ago

US FDA approves Kura Oncology's blood cancer therapy

Kura Oncology to Participate in Upcoming Investor Conference

Nov 12, 2025, 4:05 PM EST - 3 months ago

Kura Oncology to Participate in Upcoming Investor Conference

Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 3:46 PM EST - 3 months ago

Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript

Kura Oncology Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 6:31 AM EST - 3 months ago

Kura Oncology Reports Third Quarter 2025 Financial Results

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

Nov 3, 2025, 4:02 PM EST - 4 months ago

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

Nov 3, 2025, 9:14 AM EST - 4 months ago

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

Kura Oncology's Ziftomenib Poised For Differentiation

Nov 2, 2025, 9:00 AM EST - 4 months ago

Kura Oncology's Ziftomenib Poised For Differentiation

Kura Oncology to Report Third Quarter 2025 Financial Results

Oct 28, 2025, 4:01 PM EDT - 4 months ago

Kura Oncology to Report Third Quarter 2025 Financial Results

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Oct 24, 2025, 7:02 AM EDT - 4 months ago

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript

Oct 18, 2025, 6:56 PM EDT - 4 months ago

Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 18, 2025, 3:23 AM EDT - 4 months ago

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript

Oct 1, 2025, 5:02 PM EDT - 5 months ago

Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Oct 1, 2025, 7:01 AM EDT - 5 months ago

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

Sep 29, 2025, 4:01 PM EDT - 5 months ago

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

Sep 25, 2025, 5:18 PM EDT - 5 months ago

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy

Sep 19, 2025, 11:03 AM EDT - 5 months ago

Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy

Kura Oncology, Inc. - Special Call

Sep 16, 2025, 10:53 PM EDT - 5 months ago

Kura Oncology, Inc. - Special Call

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Sep 16, 2025, 4:01 PM EDT - 5 months ago

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 4:44 PM EDT - 5 months ago

Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Sep 3, 2025, 8:02 AM EDT - 6 months ago

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Kura Oncology to Participate in Three Upcoming Investor Conferences

Aug 28, 2025, 7:30 AM EDT - 6 months ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 10:46 PM EDT - 7 months ago

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Kura Oncology Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Kura Oncology Reports Second Quarter 2025 Financial Results

Kura Oncology to Report Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 7 months ago

Kura Oncology to Report Second Quarter 2025 Financial Results

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Jul 2, 2025, 12:09 AM EDT - 8 months ago

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Jun 12, 2025, 7:30 AM EDT - 9 months ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

Jun 2, 2025, 6:00 PM EDT - 9 months ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Jun 1, 2025, 7:00 PM EDT - 9 months ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 22, 2025, 5:30 PM EDT - 9 months ago

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 14, 2025, 10:00 AM EDT - 10 months ago

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 6, 2025, 7:30 AM EDT - 10 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

May 1, 2025, 8:48 PM EDT - 10 months ago

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

Kura Oncology Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 10 months ago

Kura Oncology Reports First Quarter 2025 Financial Results

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Apr 28, 2025, 7:30 AM EDT - 10 months ago

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Kura Oncology to Report First Quarter 2025 Financial Results

Apr 24, 2025, 7:30 AM EDT - 10 months ago

Kura Oncology to Report First Quarter 2025 Financial Results

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Apr 8, 2025, 7:30 AM EDT - 11 months ago

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Apr 1, 2025, 7:30 AM EDT - 11 months ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Mar 26, 2025, 7:30 AM EDT - 11 months ago

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

PennyPoacher
PennyPoacher Feb. 23 at 9:27 PM
$KURA has there been a PR that states when ER is? Or does the company not PR a date/time for that?
1 · Reply
biochirp
biochirp Feb. 23 at 7:23 PM
$KURA cash position almost as high as the market cap, buy a drug launch for free at these prices
0 · Reply
Olena
Olena Feb. 23 at 6:31 PM
$KURA have a feeling it will tank in this er temporarily. Will load …
0 · Reply
maybeme54
maybeme54 Feb. 23 at 4:09 PM
$KURA Forecasted KURA Stock Price (March 2026 - 12 Month Outlook) Average Target: ~$28.00–$32.45 High Estimate: $40.00–$76.00 Low Estimate: $16.00–$20.00
0 · Reply
Olena
Olena Feb. 22 at 8:08 PM
$KURA https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-highlights-recent-accomplishments-preliminary
0 · Reply
Olena
Olena Feb. 21 at 8:00 PM
$KURA will it take another 12 months for it to reach $16-20?
1 · Reply
Zvizdamat
Zvizdamat Feb. 20 at 5:50 PM
$KURA $SNDX you are welcome!
2 · Reply
Oscarca
Oscarca Feb. 20 at 2:31 PM
$KURA
0 · Reply
AdiDasRom
AdiDasRom Feb. 20 at 10:36 AM
$KURA
0 · Reply
quickaspeter
quickaspeter Feb. 19 at 1:27 PM
$KURA - FDA will drop two-study requirement for new drug approvals, aiming to speed access. - Going forward, the FDA’s “default position” will be to require one study for new drugs and other novel health products, FDA Commissioner Dr. Marty Makary and a top deputy, Dr. Vinay Prasad, wrote in a New England Journal of Medicine piece published Wednesday February 18, 2026.
1 · Reply
fatpie68
fatpie68 Feb. 18 at 4:45 PM
Red candle for $KURA today but still Higher Highs and Higher Lows to keep the daily chart looking good. Terrible volume today too. If the ER next week is a beat, this stock rips.
0 · Reply
MarySosa435
MarySosa435 Feb. 18 at 12:57 PM
$KURA Oncology biotech with late-stage assets; regulatory execution matters.
0 · Reply
elmono
elmono Feb. 17 at 4:45 PM
$KURA makes my top5 of most undervalued early commercial biotech
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 16 at 10:53 PM
$KURA Current Stock Price: $8.32 Contracts to trade: $8.0 KURA Feb 20 2026 Call Entry: $0.23 Exit: $0.42 ROI: 85% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ITrustno1
ITrustno1 Feb. 16 at 9:47 PM
$KURA hopefully that was the end of the $7’s… snow forecast here in the PNW this week …perfect timing for TRACTION
0 · Reply
TheYoungGeologist
TheYoungGeologist Feb. 14 at 4:40 PM
$KURA got my eyes on this one as a discounted sales story, what do those that have been here awhile think?
1 · Reply
Regard1plus1is5
Regard1plus1is5 Feb. 14 at 3:36 PM
$KURA this is on the radar
0 · Reply
fatpie68
fatpie68 Feb. 14 at 1:02 PM
$KURA Institutional Ownership increased 1.9% while Short Interest increased 1.57% over the past week. Now that Institutional Ownership is above 99% - I do not understand why the FatCats would want to short the stock to keep the share price low. I expect that Short Interest percentage (currently 16.19%) to drop by more than half before the upcoming ER.
0 · Reply
Olena
Olena Feb. 14 at 3:47 AM
$KURA Key Catalyst Dates Feb 25, 2026 (Estimated): Q4 2025 Earnings Release. Early 2026: Continued commercial launch and revenue reporting for Komzifti (ziftomenib) following its FDA approval in Nov 2025. H1 2026 (Anticipated): Further data from trials of ziftomenib in combination regimens and other indications. Ongoing 2026: Progress on Phase 3 COMET-17 front-line trials.
0 · Reply
Olena
Olena Feb. 14 at 1:33 AM
$KURA this could be an investment not a daily trade…💰💰💰💰
0 · Reply
AdiDasRom
AdiDasRom Feb. 13 at 8:48 PM
$KURA
0 · Reply
Olena
Olena Feb. 13 at 7:10 PM
$KURA https://www.google.com/search?q=kura+forecast+2026&ie=UTF-8&oe=UTF-8&hl=en-us&client=safari#lfId=ChxjMe
0 · Reply